Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Atlas Salt Expands MOU with Sandvik Mining Supporting Great Atlantic Salt Project (click to learn more) Digital Health Meets AI -CSE: ALEN.U (click to learn more) New Gold Opportunities in the Cariboo Region (CSE:GCC) (OTC:GCCFF) (click to learn more) Why Herbal Dispatch (CSE:HERB) Is Getting Attention (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Senti Biosciences Inc SNTI

Healthcare Biotechnology
Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:SNTI)

Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

GlobeNewswire 2 days ago

Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026

GlobeNewswire 10 days ago

Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation

GlobeNewswire January 14, 2026

Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference

GlobeNewswire January 9, 2026

Senti Biosciences Announces New Employment Inducement Grants

GlobeNewswire December 18, 2025

Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile

GlobeNewswire December 9, 2025

Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia

GlobeNewswire December 9, 2025

Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ET

GlobeNewswire December 4, 2025

Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December

GlobeNewswire November 13, 2025
View More News ››

Opinion & Analysis (NDAQ:SNTI)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:SNTI)

Buy buddy buy.

Otherwise FOMO for you guys out there
coolfooldumbguy - July 14, 2025

Using technical analysis for this stock.

Watching and waiting for an uptrend for it today and tomorrow,so
coolfooldumbguy - June 19, 2025

$SNTI Slips, $MYNZ Builds for the Future

$SNTI falls 29% to $7.14 amid concerns in synthetic biology progress. Meanwhile, $MYNZ, post-reverse split, is regaining strength...
SkyProfit12 - December 4, 2024

SNTI Kaboom!! SPAI News

SNTI Kaboom!! SPAI News
10QKing - December 2, 2024

Senti Biosciences, Inc. (NASDAQ:SNTI): A Promising Gene Circ

http://beyondspx.com/2024/08/01/senti-biosciences-inc-nasdaqsnti-a-promising-gene-circuit-platform-with-significant-potential/
MikeTester - August 2, 2024
View more Bullboard ››

Osisko Development Corp.

Osisko Development Corp.

Osisko Development Corp. is a continental North American gold development company focused on past-producing mining camps ...
View More »

Podcasts